Light-based medical start-up, LightOx revealed the appointment of two new Non-Executive Directors, alongside their successfully closing of a seven-figure funding round.
Mr Paul Lelieveld and Dr Frans van Dalen have joined the North East based company, to support the development of new light-activated drugs and fluorescent probes being produced at the company.
The addition of these two new Non-Executive Directors provides LightOx with further expert knowledge in the pharmaceutical development, regulatory pathways and the investment community – which will continue their growth.
LightOx also successfully closed its current funding round with Dutch Biopharma specialists, Meneldor acting as the lead. The medical start-up’s investment will aid the commercialisation of LightOx Probes in research markets and the development of new drugs for head, neck and skin cancers.
The growing company, established in 2016, has been researching novel compounds that have a unique function within our cells for over 8 years. LightOx CEO, Dr Sam Whitehouse, said: “We are delighted to welcome Paul and Frans to the team.
“Their wealth of experience will help us to accelerate our activities in both commercialising our LightOx Probes to a global customer base, and our development of new therapeutics which are activated by light.
“We look forward to a long and productive future with our new NEDs.”
Non-Executive Director, Mr Paul Lelieveld, added: “We are pleased to announce our investment in LightOx Ltd.
“We very much look forward to working with the highly experienced management team, and together bringing multiple LightOx-based medicines to patients in the future.”
For more information, visit www.lightox.co.uk